pentetic acid has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Daino, K; Furukawa, T; Hasegawa, S; Kamada, T; Li, HK; Morokoshi, Y; Saga, T | 1 |
1 review(s) available for pentetic acid and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pentetic acid and bortezomib
| Article | Year |
|---|---|
Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.
Topics: Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Indium Radioisotopes; Molecular Targeted Therapy; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pentetic Acid; Protein Kinase Inhibitors; Radioimmunotherapy; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Transcriptome; Trastuzumab | 2015 |